Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etirinotecan Pegol (Nektar Therapeutics)
- Development stage
- Phase 2
- Lead developer
- Nektar Therapeutics
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Etirinotecan Pegol, also known as NKTR-102, is a topoisomerase I inhibitor-polymer conjugate developed by Nektar Therapeutics. It is a PEGylated chemotherapy where irinotecan is sterically placed on a four-armed polyethylene glycol (PEG). This novel formulation provides favorable pharmacokinetics compared to native irinotecan, including reduced enzymatic breakdown and renal clearance, leading to extended drug circulation times and sustained exposure of its active metabolite, SN38, in tumors. It has been evaluated in clinical trials for various cancers, including metastatic breast cancer and lung cancer.
- Brand names
- Onzeald
- Other names
- pegylated irinotecanPEG-irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on Etirinotecan Pegol (Nektar Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etirinotecan Pegol (Nektar Therapeutics).